HCG Stock Overview
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
HealthCare Global Enterprises Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹350.25 |
| 52 Week High | ₹401.00 |
| 52 Week Low | ₹260.00 |
| Beta | 0.31 |
| 1 Month Change | 3.84% |
| 3 Month Change | -1.44% |
| 1 Year Change | 29.72% |
| 3 Year Change | 97.21% |
| 5 Year Change | 74.78% |
| Change since IPO | 104.82% |
Recent News & Updates
Recent updates
HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next
Feb 11
We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation
Sep 14A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)
Sep 05HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price
May 17Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?
Jun 24Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings
Jun 03Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?
Dec 08What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?
Jun 25Insider Buying: The HealthCare Global Enterprises Limited (NSE:HCG) Executive Chairman Just Bought ₹2.4m Worth Of Shares
Mar 14The HealthCare Global Enterprises (NSE:HCG) Share Price Is Up 51% And Shareholders Are Holding On
Mar 03Here's Why HealthCare Global Enterprises (NSE:HCG) Can Afford Some Debt
Jan 27How Many HealthCare Global Enterprises Limited (NSE:HCG) Shares Did Insiders Buy, In The Last Year?
Dec 23
Reflecting on HealthCare Global Enterprises' (NSE:HCG) Share Price Returns Over The Last Three Years
Nov 10What Type Of Shareholders Own The Most Number of HealthCare Global Enterprises Limited (NSE:HCG) Shares?
Sep 18HealthCare Global Enterprises' (NSE:HCG) Shareholders Are Down 52% On Their Shares
Aug 07Shareholder Returns
| HCG | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -4.9% | 1.3% | 2.8% |
| 1Y | 29.7% | 64.0% | 46.6% |
Return vs Industry: HCG underperformed the Indian Healthcare industry which returned 64% over the past year.
Return vs Market: HCG underperformed the Indian Market which returned 46.6% over the past year.
Price Volatility
| HCG volatility | |
|---|---|
| HCG Average Weekly Movement | 4.9% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: HCG has not had significant price volatility in the past 3 months.
Volatility Over Time: HCG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 6,136 | Raj Gore | www.hcgoncology.com |
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat; operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine, and pulmonary and critical care.
HealthCare Global Enterprises Limited Fundamentals Summary
| HCG fundamental statistics | |
|---|---|
| Market cap | ₹48.78b |
| Earnings (TTM) | ₹352.59m |
| Revenue (TTM) | ₹18.59b |
138.4x
P/E Ratio2.6x
P/S RatioIs HCG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCG income statement (TTM) | |
|---|---|
| Revenue | ₹18.59b |
| Cost of Revenue | ₹8.88b |
| Gross Profit | ₹9.71b |
| Other Expenses | ₹9.36b |
| Earnings | ₹352.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.53 |
| Gross Margin | 52.24% |
| Net Profit Margin | 1.90% |
| Debt/Equity Ratio | 113.9% |
How did HCG perform over the long term?
See historical performance and comparison